Muto Yusuke, Kitano Shigehisa
Dept. of Dermatologic Oncology, National Cancer Center Hospital.
Gan To Kagaku Ryoho. 2019 Jun;46(6):1011-1015.
Ipilimumab is the%ldquo;first in class"immune checkpoint inhibitors, which blocks cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4)to potentiate an anti-tumor effect of effector Tcells. Recently, the combination therapy with ipilimumab and anti- PD-1 antibody showed clinical benefit in some malignant tumors, advanced melanoma and renal cell cancer and so on. In this paper, we described clinical development of ipilimumab as the combination therapy including effectiveness and safety.
伊匹单抗是“同类首创”的免疫检查点抑制剂，它可阻断细胞毒性T淋巴细胞相关抗原4（CTLA-4），从而增强效应T细胞的抗肿瘤作用。最近，伊匹单抗与抗PD-1抗体的联合疗法在一些恶性肿瘤，如晚期黑色素瘤和肾细胞癌等中显示出临床益处。在本文中，我们描述了伊匹单抗作为联合疗法的临床进展，包括有效性和安全性。
